Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 22046294)

1.

Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help.

Côté AL, Byrne KT, Steinberg SM, Zhang P, Turk MJ.

PLoS One. 2011;6(10):e26491. doi: 10.1371/journal.pone.0026491. Epub 2011 Oct 26.

2.

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Byrne KT, Côté AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff MS, Usherwood EJ, Turk MJ.

J Clin Invest. 2011 May;121(5):1797-809. doi: 10.1172/JCI44849. Epub 2011 Apr 11.

4.

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Zhang P, Côté AL, de Vries VC, Usherwood EJ, Turk MJ.

Cancer Res. 2007 Jul 1;67(13):6468-76.

5.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

6.

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.

Côté AL, Zhang P, O'Sullivan JA, Jacobs VL, Clemis CR, Sakaguchi S, Guevara-Patiño JA, Turk MJ.

J Immunol. 2011 Jan 1;186(1):275-83. doi: 10.4049/jimmunol.1001308. Epub 2010 Nov 24.

7.
8.

Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Byrne KT, Zhang P, Steinberg SM, Turk MJ.

J Immunol. 2014 Feb 15;192(4):1433-9. doi: 10.4049/jimmunol.1302139. Epub 2014 Jan 8.

9.

The opposite effect of tumor-infiltrating natural killer cells on in vivo priming of tumor-specific CD8+ T cells and CD4+ T cells.

Terao H, Harada M, Kurosawa S, Shinomiya Y, Ito O, Tamada K, Takenoyama M, Nomoto K.

Immunobiology. 1996 Jul;195(2):172-86.

PMID:
8877394
10.

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.

Hu HM, Winter H, Urba WJ, Fox BA.

J Immunol. 2000 Oct 15;165(8):4246-53.

11.

Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

Muccioli M, Longstaff C, Benencia F.

Immunotherapy. 2012 May;4(5):477-81. doi: 10.2217/imt.12.39.

12.

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN.

Cancer Res. 2006 May 1;66(9):4904-12.

13.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.

PMID:
12937899
14.

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.

DiLillo DJ, Yanaba K, Tedder TF.

J Immunol. 2010 Apr 1;184(7):4006-16. doi: 10.4049/jimmunol.0903009. Epub 2010 Mar 1.

15.

Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60.

Ryu SJ, Jung KM, Yoo HS, Kim TW, Kim S, Chang J, Choi EY.

Blood. 2009 Apr 30;113(18):4273-80. doi: 10.1182/blood-2008-09-181263. Epub 2009 Jan 12.

17.

CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.

Sfondrini L, Besusso D, Bronte V, Macino B, Rossini A, Colombo MP, Ménard S, Balsari A.

Cancer Immunol Immunother. 2004 Aug;53(8):697-704. Epub 2004 Mar 18.

PMID:
15034674
18.
19.
20.

Archaeosome adjuvant overcomes tolerance to tumor-associated melanoma antigens inducing protective CD8 T cell responses.

Krishnan L, Deschatelets L, Stark FC, Gurnani K, Sprott GD.

Clin Dev Immunol. 2010;2010:578432. doi: 10.1155/2010/578432. Epub 2011 Jan 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk